

## **Results of the General Shareholders' Meeting held on June 16, 2017 Appointment of Jean M. Franchi to the Board of Directors**

**Paris, June 16<sup>th</sup> June, 2017, 6pm – BIOPHYTIS (Alternext Paris: ALBPS), biotechnology company specialized in the development of drug candidates to treat aging diseases, is pleased to announce the approval of all key resolutions submitted to shareholders during the Combined General shareholders' Meeting of June 16, 2017, particularly one related to the appointment of Ms Jean M. Franchi as a member of the Biophytis Board of Directors.**

The shareholders present or represented taking part in the vote altogether owned 2,756,157 shares and 2,756,157 voting rights, i.e. 31.08% of voting rights.

The shareholders approved either unanimously or by a very large majority all of the resolutions (with the exception of resolutions 6 and 16), including one ratifying the nomination of Ms. Jean M. Franchi as a Director of Biophytis for a duration of 3 years.

After the appointment to the scientific committee of Pr Roger Fielding and Dr Ivana Kim, two leading US scientists, in 2016, the appointment of Jean M. Franchi as Director strengthens the international profile of the Board of Directors, and demonstrates Biophytis' foothold and development strategy in the United States.

Jean M. Franchi has more than 30 years of experience in the financial management of biotechnology companies. For more than 15 years she mainly filled roles at Genzyme in financial management, actively participating in the development of the company that has become a leading biotechnology company in the treatment of rare diseases, until it was bought out by Sanofi in 2011. She is currently Financial Director of Dimension Therapeutics, a biotechnology company that she introduced onto the NASDAQ stock exchange in 2015.

Other key resolutions approved were:

- The social and consolidated accounts for fiscal year 2016
- The allocation of profit for the fiscal year ended December 31, 2016
- The delegations of financial authority and authorisations granted to the Board of Directors

Full results of votes on resolutions will be available on the Company's website as of June 16<sup>th</sup>, 2017, in the « Investors / Regulated information » section.

\*\*\*

### About BIOPHYTIS:

Biophytis SA ([www.biophytis.com](http://www.biophytis.com)), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS ; ISIN: FR0012816825).



### Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website ([www.amf-france.org](http://www.amf-france.org)) or on BIOPHYTIS' website ([www.biophytis.com](http://www.biophytis.com)).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.

**BIOPHYTIS**  
**Stanislas VEILLET**  
CEO  
contact@biophytis.com  
Tel : +33 (0) 1 41 83 66 00

**Citigate Dewe Rogerson**  
**International media**  
**Laurence BAULT/Antoine DENRY**  
[Laurence.bault@citigate.fr](mailto:Laurence.bault@citigate.fr)/[antoine.denry@citigate.fr](mailto:antoine.denry@citigate.fr)  
Tel : +33 (0)1 53 32 84 78  
Mob : +33(0)6 64 12 53 61

**LifeSci Advisors**  
**Chris MAGGOS**  
Managing Director, Europe  
chris@lifesciadvisors.com  
Tel : +41 79 367 6254

**Milestones**  
**Media & Investor relations**  
**Bruno ARABIAN**  
barabian@milestones.fr  
Tel : +33 (0) 1 83 62 34 84  
Mob : +33 (0) 6 87 88 47 26